- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
- Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- POS0693 MORTALITY RATE IN PATIENTS WITH GIANT CELL ARTERITIS IN SPAIN: CAUSES AND ASSOCIATED FACTORS FROM THE ARTESER REGISTRY
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Scientific Abstracts
Poster View
Vasculitis, large vessels including polymyalgia rheumatica
POS0693 MORTALITY RATE IN PATIENTS WITH GIANT CELL ARTERITIS IN SPAIN: CAUSES AND ASSOCIATED FACTORS FROM THE ARTESER REGISTRY
- J. Molina-Collada1,
- M. Dominguez-Alvaro2,
- R. B. Melero-González3,
- E. De Miguel4,
- M. Silva-Díaz5,
- J. A. Valero Jaimes6,
- I. González7,
- J. Sanchez-Martín8,
- J. Narváez9,
- J. Calvet10,
- I. Casafont-Solé11,
- J. A. Román-Ivorra12,
- S. Labrada-Arrabal13,
- M. Vasques-Rocha14,
- C. L. Iñiguez15,
- S. Bustabad Reyes16,
- C. Campos Fernández17,
- M. Alcalde Villar18,
- A. J. Mas19,
- R. Blanco20,
- on behalf of ARTESER Project Collaborative Group
- 1Hospital General Universitario Gregorio Marañón. Madrid, Spain, Rheumatology, Madrid, Spain
- 2Sociedad Española de Reumatología, Research Unit, Madrid, Spain
- 3Complexo Hospitalario Universitario de Ourense, Rheumatology, Ourense, Spain
- 4Hospital Universitario La Paz, Rheumatology, Madrid, Spain
- 5Complejo Hospitalario Universitario de A Coruña, Rheumatology, La Coruña, Spain
- 6Hospital Universitario Donosti, Rheumatology, Donostia, Spain
- 7Hospital Universitario de León, Rheumatology, León, Spain
- 8Hospital Universitario Marqués de Valdecilla. IDIVAL Immunopathology group, Rheumatology, Santander, Spain
- 9Hospital Universitari Bellvitge. Hospitalet de Llobregat, Rheumatology, Barcelina, Spain
- 10Hospital Universitario Parc Tauli, Rheumatology, Barcelona, Spain
- 11Hospital Universitario Germans Trias i Pujol, Rheumatology, Barcelona, Spain
- 12Hospital Universitari i Politècnic La Fe, Rheumatology, Valencia, Spain
- 13Hospital del Mar, Rheumatology, Barcelona, Spain
- 14Hospital Universitario Araba, Rheumatology, Vitoria-Gasteiz, Spain
- 15Hospital Universitario Lucus Augusti, Rheumatology, Lugo, Spain
- 16Hospital Universitario de Canarias, Rheumatology, La Laguna, Spain
- 17Consorci Hospital General Universitari de València, Rheumatology, Valencia, Spain
- 18Hospital Universitario Severo Ochoa Leganés, Rheumatology, Madrid, Spain
- 19Hospital Universitari Son Llàtzer, Rheumatology, Palma de Mallorcas, Spain
- 20Hospital Universitario Marqués de Valdecilla. IDIVAL Immunopathology group., Rheumatology, Santander, Spain
Abstract
Background: The outcomes of epidemiologic studies on giant cell arteritis (GCA) patients display notable heterogeneity regarding the mortality rate and distinct patterns of cause-specific death, underscoring the need for further investigation and a more comprehensive understanding of these critical aspects.
Objectives: To analyze the mortality rate in patients with GCA in Spain and determine the causes of death and associated mortality factors.
Methods: ARTESER is a large Spanish multicenter registry promoted by the Spanish Society of Rheumatology, including patients with GCA diagnosis from June 2013 to March 2019. The following variables were collected at diagnosis and during follow-up per protocol: demographics, presenting symptoms, laboratory test results, temporal artery biopsy and imaging techniques (ultrasound, PET, MRI, CT), death and cause of death. For the purpose of this study, only patients who completed the follow-up visits were included in the analysis. Kaplan-Meier and Cox regression were performed for survival analysis. The factors associated with mortality were analyzed in both univariable and multivariable analyses.
Results: A total of 1200 patients with GCA from the ARTESER registry were analyzed, with mean (SD) follow-up of 2.18 (1.53) years. 142 deaths were recorded during the follow-up assessments. The overall mortality rate (95% CI) was 11.83 (10.00 – 13.66) per 100 patients, being 17.81 (13.86 – 21.75) in males and 11.83 (7.26 – 11.19) in females. Figure 1 shows the Kaplan-Meier survival rate during follow-up. The most common causes of death were infections (31%), malignancies (16%) and cardiovascular diseases (11.3%). In the multivariate analysis (Table 1), older age was the only clinical variable associated with increased mortality (HR 1.11, 95% CI 1.077 - 1.143). Female sex (HR 0.54 95% CI 0.376 - 0.782), the presence of headache (HR 0.61, 95% CI 0.406 - 0.916) and high hemoglobin levels (HR 0.85, 95% CI 0.748 - 0.967) were protective factors for death.
Conclusion: The overall GCA mortality rate in Spain is 11.83 per 100 patients, with infection being the most frequent cause of death. Older age is associated with an increased risk of mortality, whereas female sex, headache, and high hemoglobin levels were identified as protective factors against death.
REFERENCES: NIL.
View this table:
- View inline
- View popup
Table 1.
Multivariable analysis of factors associated with mortality in patients with GCA. HR: Hazard ratio
- Download figure
- Open in new tab
- Download powerpoint
Figure 1.
Kaplan-Meier survival rate in patients with GCA included in the ARTESER registry
Acknowledgements: The authors thank Javier Prado Galbarro for the statistical analysis.
Disclosure of Interests: Juan Molina-Collada: None declared, Marta Dominguez-Alvaro: None declared, Rafael B Melero-González: None declared, Eugenio De Miguel Abbvie, Novartis, Roche, Pfizer, Janssen, Lilly, MSD, BMS, UC Pharma, Grünenthal and Sanofi, Maite Silva-Díaz: None declared, Jesús Alejandro Valero Jaimes: None declared, Ismael González: None declared, Julio Sanchez-Martín: None declared, Javier Narváez: None declared, Joan Calvet: None declared, Ivette Casafont-Solé: None declared, Jose Andrés Román-Ivorra: None declared, Selene Labrada-Arrabal: None declared, Margarida Vasques-Rocha: None declared, Carlota L Iñiguez Pfizer, AbbVie, Fresenius - Kiabi, Novartis, GSK, Sanofi y Janssen, Sagrario Bustabad Reyes: None declared, Cristina Campos Fernández: None declared, María Alcalde Villar: None declared, Antonio Juan Mas: None declared, Ricardo Blanco AbbVie, Pfizer, Roche, Lilly, UCB, Bristol-Myers, Janssen, and MSD., AbbVie, MSD, and Roche.
- Real-world evidence
- Epidemiology
- Outcome measures
- Registries
- Observational studies/registry
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Real-world evidence
- Epidemiology
- Outcome measures
- Registries
- Observational studies/registry
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens